Tjip S van der Werf
Overview
Explore the profile of Tjip S van der Werf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
214
Citations
3823
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Vogensen V, Bolhuis M, Sturkenboom M, van der Werf T, de Lange W, Anthony R, et al.
Antimicrob Agents Chemother
. 2021 Nov;
66(2):e0182921.
PMID: 34807758
Moxifloxacin is an attractive drug for the treatment of isoniazid-resistant rifampicin-susceptible tuberculosis (TB) or drug-susceptible TB complicated by isoniazid intolerance. However, co-administration with rifampicin decreases moxifloxacin exposure. It remains unclear...
12.
Martson A, Edwina A, Burgerhof J, Berger S, de Joode A, Damman K, et al.
J Antimicrob Chemother
. 2021 Jun;
76(9):2356-2363.
PMID: 34160036
Background: The use of (val)ganciclovir is complicated by toxicity, slow response to treatment and acquired resistance. Objectives: To evaluate a routine therapeutic drug monitoring (TDM) programme for ganciclovir in a...
13.
Al-Kailany W, Timens W, Venmans B, de Jonge G, van der Werf T
J Med Case Rep
. 2021 May;
15(1):232.
PMID: 33971963
Background: Patients with pulmonary sarcoidosis commonly present with a dry cough; a productive cough suggests a complicating airway infection or an alternative diagnosis such as tuberculosis or bronchiectasis. Case Presentation:...
14.
Prins H, Duijkers R, Daniels J, van der Molen T, van der Werf T, Boersma W
BMJ Open Respir Res
. 2021 Feb;
8(1).
PMID: 33593795
Background: We developed the chronic obstructive pulmonary disease (COPD)-Lower Respiratory Tract Infection-Visual Analogue Score (c-LRTI-VAS) in order to easily quantify symptoms during exacerbations in patients with COPD. This study aimed...
15.
16.
Ghimire S, Karki S, Maharjan B, Kosterink J, Touw D, van der Werf T, et al.
BMJ Open Respir Res
. 2020 Aug;
7(1).
PMID: 32796020
Objectives: The objectives of this study were to evaluate treatment in patients on current programmatic multidrug-resistant tuberculosis (MDR-TB) regimen and verify eligibility for the 9-month regimen and therapeutic drug monitoring...
17.
Martson A, van der Elst K, Veringa A, Zijlstra J, Beishuizen A, van der Werf T, et al.
Antimicrob Agents Chemother
. 2020 Jul;
64(9).
PMID: 32660990
The objective of this study was to develop a population pharmacokinetic model and to determine a dosing regimen for caspofungin in critically ill patients. Nine blood samples were drawn per...
18.
Akkerman O, van der Werf T, Rietkerk F, Eger T, van Soolingen D, van der Loo K, et al.
Med Microbiol Immunol
. 2020 Jul;
209(6):705.
PMID: 32648095
The original article can be found online.
19.
van den Elsen S, Sturkenboom M, Akkerman O, Barkane L, Bruchfeld J, Eather G, et al.
BMJ Open
. 2020 Jun;
10(6):e035350.
PMID: 32554740
Introduction: Global multidrug-resistant tuberculosis (MDR-TB) treatment success rates remain suboptimal. Highly active WHO group A drugs moxifloxacin and levofloxacin show intraindividual and interindividual pharmacokinetic variability which can cause low drug...
20.
Bolhuis M, van der Werf T, Akkerman O
N Engl J Med
. 2020 Jun;
382(24):2376-2377.
PMID: 32521142
No abstract available.